Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and βklotho agonist antibodies

• Published in: Biochemical and biophysical research communications 2017-05, Vol.486 (4), p.985-991
• Main Authors: Grujic, Ognjen, Stevens, Jennitte, Chou, Robert Y.-T., Weiszmann, Jennifer V., Sekirov, Laura, Thomson, Christy, Badh, Anita, Grauer, Stephanie, Chan, Brian, Graham, Kevin, Manchulenko, Kathy, Dillon, Thomas M., Li, Yang, Foltz, Ian N.
• Format: Article
• Language: English
• Subjects: Agonist; Animals; Antibodies, Monoclonal - chemistry; Antibodies, Monoclonal - immunology; Antibody isoform; Antigens, Surface - chemistry; Antigens, Surface - immunology; CD200R; CHO Cells; Cricetulus; Disulfides - chemistry; Disulfides - immunology; Epitope Mapping - methods; Membrane Proteins - chemistry; Membrane Proteins - immunology; Protein Isoforms - chemistry; Protein Isoforms - immunology; Receptors, Cell Surface - chemistry; Receptors, Cell Surface - immunology; Structure-Activity Relationship; Subclass; βklotho
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2017.03.145

Agonism of cell surface receptors by monoclonal antibodies is dependent not only on its ability to bind the target, but also to deliver a biological signal through receptors to the cell. Immunoglobulin G2 antibodies (IgG2s) are made up of a mixture of distinct isoforms (IgG2-A, -B and A/B), which differ by the disulfide connectivity at the hinge region. When evaluating panels of agonistic antibodies against CD200 receptor (CD200R) or βklotho receptor (βklotho), we noticed striking activity differences of IgG1 or IgG2 antibodies with the same variable domains. For the CD200R antibody, the IgG2 antibody demonstrated higher activity than the IgG1 or IgG4 antibody. More significantly, for βklotho, agonist antibodies with higher biological activity as either IgG2 or IgG1 were identified. In both cases, ion exchange chromatography was able to isolate the bioactivity to the IgG2-B isoform from the IgG2 parental mixture. The subclass-related increase in agonist activity was not correlated with antibody aggregation or binding affinity, but was driven by enhanced avidity for the CD200R antibody. These results add to the growing body of evidence that show that conformational differences in the antibody hinge region can have a dramatic impact on the antibody activity and must be considered when screening and engineering therapeutic antibody candidates. The results also demonstrate that the IgG1 (IgG2-A like) or the IgG2-B form may provide the most active form of agonist antibodies for different antibodies and targets. •Antibody subclass and disulfide isoform affect CD200R and βklotho agonist activity.•IgG1 (IgG2-A) or IgG2-B form may be the most active form of agonist antibodies.•Activity does not correlate with binding affinity or aggregation.•Activity may depend on binding avidity and antibody binding epitope.•Antibody subclass choice should be considered when screening agonist antibodies.